BerGenBio announces advancement of its strategic review
Bergen, Norway, March 17, 2025 – Reference is made to the stock exchange announcement on 25 February 2025 from BerGenBio ASA (OSE: BGBIO) (the "Company"), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for serious diseases, in which the Company amongst other things announced that it will explore strategic alternatives. The Company today announced that it has engaged Carnegie AS[i], an entity within the DNB Bank ASA group, as its financial advisor to assist in the Company’s review of strategic alternatives. The management and Board of Directors of the Company have together with Carnegie initiated exploration of potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, sale of assets, licensing, or other transactions. The Company does not intend to disclose further developments unless and until it is determined that further disclosure is appropriate or legally required.
The Company also announces that it has already implemented significant cost-containment and cash conservation measures.
Contacts
Olav Hellebø, CEO BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
Jan Lilleby, Investor Relations / Media Relations
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
[i] Part of DNB Bank ASA